nach oben

Erschienen in:

25.06.2020 | Head and Neck

Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma

verfasst von: Sahrish Qamar, Ann D. King, Qi-Yong H. Ai, Frankie Kwok Fai Mo, Weitian Chen, Darren M. C. Poon, Macy Tong, Brigette B. Ma, David Ka-Wai Yeung, Yi-Xiang Wang, Jing Yuan

Erschienen in: European Radiology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the value of pre-treatment amide proton transfer–weighted (APTw) imaging for predicting survival of patients with nasopharyngeal carcinoma (NPC).

Materials and methods

Pre-treatment APTw imaging was performed in 77 NPC patients and the mean, 90th percentile, skewness, and kurtosis of APT asymmetry (APT_mean, APT₉₀, APT_skewness, and APT_kurtosis, respectively) were obtained from the primary tumor. Associations of APTw parameters with locoregional relapse–free survival (LRRFS), distant metastasis–free survival (DMFS), and disease-free survival (DFS) after 2 years were assessed by univariable Cox regression analysis and significant APTw parameters, together with age, sex, treatment, and stage as confounding variables, were added to the multivariable model. Kaplan-Meier analysis was used to determine the prognostic significance of patients with high or low APT values based on a threshold value from receiver operating characteristic curve analysis.

Results

Locoregional relapse, distant metastases, and disease relapse occurred in 14/77 (18%), 10/77 (13%), and 20/77 (26%) patients, respectively, at a median follow-up of 48.3 (10.6–67.4) months. Univariable analysis showed significant associations of LRRFS with APT_skewness (HR = 1.98; p = 0.034), DMFS with APT_mean (HR = 2.44; p = 0.033), and APT₉₀ (HR = 1.93; p = 0.009), and DFS with APT_mean (HR = 2.01; p = 0.016), APT₉₀ (HR = 1.68; p = 0.009), and APT_skewness (HR = 1.85; p = 0.029). In multivariable analysis, the significant predictors for DMFS were APT₉₀ (HR = 3.51; p = 0.004) and nodal stage (HR = 5.95; p = 0.034) and for DFS were APT₉₀ (HR = 1.97; p = 0.010) and age (HR = 0.92; p = 0.014). An APT₉₀ ≥ 4.38% was associated with a significantly poorer DFS at 2 years than APT₉₀ < 4.38% (66% vs. 91%; HR = 4.01; p = 0.005).

Conclusion

APTw imaging may potentially predict survival in patients with NPC.

Key Points

• APTw imaging may provide new markers to predict survival in nasopharyngeal carcinoma.

• APT₉₀ is an independent predictor of distant metastases–free survival and disease-free survival.

• The APT_high group is at higher risk of disease relapse than the APT_low group.

Nur mit Berechtigung zugänglich

Lin J-C (2012) Adjuvant chemotherapy in advanced nasopharyngeal carcinoma based on plasma EBV load. J Radiat Oncol 1:117–127CrossRef

Lee AW, Ma BB, Ng WT, Chan AT (2015) Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 33:3356–3364CrossRef

Lee VH, Kwong DL, Leung TW et al (2019) The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 144:1713–1722CrossRef

Qin Y, Yu X, Hou J et al (2019) Prognostic value of the pretreatment primary lesion quantitative dynamic contrast-enhanced magnetic resonance imaging for nasopharyngeal carcinoma. Acad Radiol. https://doi.org/10.1016/j.acra.2019.01.021

Huang TX, Lu N, Lian SS et al (2019) The primary lesion apparent diffusion coefficient is a prognostic factor for locoregionally advanced nasopharyngeal carcinoma: a retrospective study. BMC Cancer 19:470CrossRef

Zhou J, Heo HY, Knutsson L, van Zijl PCM, Jiang S (2019) APT-weighted MRI: techniques, current neuro applications, and challenging issues. J Magn Reson Imaging. https://doi.org/10.1002/jmri.26645

Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50:1120–1126CrossRef

Ray KJ, Simard MA, Larkin JR et al (2019) Tumor pH and protein concentration contribute to the signal of amide proton transfer magnetic resonance imaging. Cancer Res 79:1343–1352CrossRef

Bai Y, Lin Y, Zhang W et al (2017) Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas. Oncotarget 8:5834–5842CrossRef

10.

Jiang S, Eberhart CG, Zhang Y et al (2017) Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. Eur J Cancer 83:9–18CrossRef

11.

Sagiyama K, Mashimo T, Togao O et al (2014) In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma. Proc Natl Acad Sci U S A 111:4542–4547CrossRef

12.

Togao O, Yoshiura T, Keupp J et al (2014) Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol 16:441–448CrossRef

13.

Jiang S, Eberhart CG, Lim M et al (2019) Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: a validation study with image-guided stereotactic biopsy. Clin Cancer Res 25:552–561CrossRef

14.

Takayama Y, Nishie A, Togao O et al (2018) Amide proton transfer MR imaging of endometrioid endometrial adenocarcinoma: association with histologic grade. Radiology 286:909–917CrossRef

15.

Takayama Y, Nishie A, Sugimoto M et al (2016) Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: comparison with Gleason scores. MAGMA 29:671–679CrossRef

16.

Zhang J, Zhu W, Tain R, Zhou XJ, Cai K (2018) Improved differentiation of low-grade and high-grade gliomas and detection of tumor proliferation using APT contrast fitted from z-spectrum. Mol Imaging Biol 20:623–631CrossRef

17.

Ohno Y, Kishida Y, Seki S et al (2018) Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: comparison with diffusion-weighted imaging and FDG-PET/CT. J Magn Reson Imaging 47:1013–1021CrossRef

18.

Yu L, Li C, Luo X et al (2019) Differentiation of malignant and benign head and neck tumors with amide proton transfer-weighted MR imaging. Mol Imaging Biol 21:348–355CrossRef

19.

Law BKH, King AD, Ai QY et al (2018) Head and neck tumors: amide proton transfer MRI. Radiology 288:782–790CrossRef

20.

Kamimura K, Nakajo M, Yoneyama T et al (2018) Histogram analysis of amide proton transfer-weighted imaging: comparison of glioblastoma and solitary brain metastasis in enhancing tumors and peritumoral regions. Eur Radiol. https://doi.org/10.1007/s00330-018-5832-1

21.

Krikken E, Khlebnikov V, Zaiss M et al (2018) Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res 20:51CrossRef

22.

Nishie A, Asayama Y, Ishigami K et al (2018) Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.14315

23.

Ma B, Blakeley JO, Hong X et al (2016) Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 44:456–462CrossRef

24.

Park KJ, Kim HS, Park JE, Shim WH, Kim SJ, Smith SA (2016) Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur Radiol 26:4390–4403CrossRef

25.

Regnery S, Adeberg S, Dreher C et al (2018) Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget 9:28772–28783

26.

Kumari N, Thakur N, Cho HR, Choi SH (2019) Assessment of early therapeutic response to nitroxoline in temozolomide-resistant glioblastoma by amide proton transfer imaging: a preliminary comparative study with diffusion-weighted imaging. Sci Rep 9:5585CrossRef

27.

Joo B, Han K, Ahn SS et al (2019) Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Eur Radiol. https://doi.org/10.1007/s00330-019-06203-x

28.

Park JE, Kim HS, Park KJ, Kim SJ, Kim JH, Smith SA (2016) Pre- and posttreatment glioma: comparison of amide proton transfer imaging with MR spectroscopy for biomarkers of tumor proliferation. Radiology 278:514–523CrossRef

29.

Qamar S, King AD, Ai QY et al (2018) Amide proton transfer MRI detects early changes in nasopharyngeal carcinoma: providing a potential imaging marker for treatment response. Eur Arch Otorhinolaryngol 276:505–512CrossRef

30.

Liu R, Jiang G, Gao P et al (2018) Non-invasive amide proton transfer imaging and ZOOM diffusion-weighted imaging in differentiating benign and malignant thyroid micronodules. Front Endocrinol (Lausanne) 9:747CrossRef

31.

Yuan J, Chen S, King AD et al (2014) Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed 27:1239–1247CrossRef

32.

Bae YJ, Choi BS, Jeong WJ et al (2019) Amide proton transfer-weighted MRI in the diagnosis of major salivary gland tumors. Sci Rep 9:8349CrossRef

33.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York

34.

Chan AT, Leung SF, Ngan RK et al (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536–539CrossRef

35.

Chen Y, Li X, Song Y et al (2019) The diagnostic efficacy of amide proton transfer imaging in grading gliomas and predicting tumor proliferation. Neuroreport 30:139–144CrossRef

36.

Liu J, Li C, Chen Y et al (2019) Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T. J Magn Reson Imaging. https://doi.org/10.1002/jmri.26900

37.

Paech D, Dreher C, Regnery S et al (2019) Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol 29:4957–4967CrossRef

38.

Kamimura K, Nakajo M, Yoneyama T et al (2019) Amide proton transfer imaging of tumors: theory, clinical applications, pitfalls, and future directions. Jpn J Radiol 37:109–116CrossRef

39.

Chung WJ, Kim HS, Kim N, Choi CG, Kim SJ (2013) Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. Radiology 269:561–568CrossRef

40.

Zhu H, Jones CK, van Zijl PC, Barker PB, Zhou J (2010) Fast 3D chemical exchange saturation transfer (CEST) imaging of the human brain. Magn Reson Med 64:638–644CrossRef

41.

Chen X, Wei X, Liu L et al (2020) Comparison of the reproducibility of 2D and 3D amide proton transfer weighted imaging in intracranial rat gliomas at 3 T. Chin J Acad Radiol. https://doi.org/10.1007/s42058-020-00028-0

42.

Zhao X, Wen Z, Zhang G et al (2013) Three-dimensional turbo-spin-echo amide proton transfer MR imaging at 3-Tesla and its application to high-grade human brain tumors. Mol Imaging Biol 15:114–122CrossRef

43.

Qu H, Huang Y, Zhao S, Zhou Y, Lv W (2020) Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol 277:9–18CrossRef

44.

Wong ECY, Hung JLC, Ng WT (2020) Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma. Head Neck 42:446–455CrossRef

45.

Wee J, Tan EH, Tai BC et al (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23:6730–6738CrossRef

46.

Chen B-B, Huang S-M, Xiao W-W et al (2018) Prospective matched study on comparison of volumetric-modulated arc therapy and intensity-modulated radiotherapy for nasopharyngeal carcinoma: dosimetry, delivery efficiency and outcomes. J Cancer 9:978–986CrossRef

Titel: Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma
verfasst von: Sahrish Qamar
Ann D. King
Qi-Yong H. Ai
Frankie Kwok Fai Mo
Weitian Chen
Darren M. C. Poon
Macy Tong
Brigette B. Ma
David Ka-Wai Yeung
Yi-Xiang Wang
Jing Yuan
Publikationsdatum: 25.06.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 11/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-06985-5

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma